Cancer Research UK logo.
SearchDonate
  • Search
This photo shows a woman opening a Faecal Imunochemical Test.
Health professionals

Last reviewed: 22 August 2025

Differences between FIT in screening and symptomatic use

Last reviewed: 22 August 2025

The Faecal Immunochemical Test (FIT) is used in two different pathways to assess the risk of colorectal cancer.

  • When people present with colorectal symptoms, FIT can detect trace amounts of blood with a low threshold for a positive result.

  • FIT is also used for asymptomatic screening with a higher positive test threshold.

Healthcare professions should ensure:

  • People with symptoms are tested in line with guidance, regardless of their bowel cancer screening results.

  • Eligible patients are encouraged to participate in bowel screening when they’re invited, even where they’ve had a negative symptomatic FIT.

How do the FIT pathways differ?

Each nation has different screening and primary care pathways where FIT is used to assess colorectal cancer risk. Click on your nation below to open our overview of the key differences on a page.

England - Screening vs. Symptomatic FIT infographic(PDF, 56.4 KB)

Scotland - screening vs. Symptomatic FIT infographic(PDF, 61.3 KB)

Wales - screening vs. Symptomatic FIT infographic(PDF, 81.4 KB)

Northern Ireland - Screening vs. Symptomatic FIT infographic(PDF, 77.6 KB)

This photo shows a GP talking to a patient about a symptomatic Faecal Imunochemical Test (FIT) kit from England.

Back to Faecal Immunochemical Test (FIT) overview

Doctor at the GP surgery talking to the patient and her carer.

Managing people in primary care

Bowel cancer screening

Access our bowel cancer screening hub for healthcare professionals for more information about the programmes.

Bowel cancer screening

Questions

Contact the Strategic Evidence team

Email us